-
The eighth batch of large-scale variety games: Pfizer, Sanofi, AstraZeneca, Coron, Yangtze River, etc. compete for the 60 billion market
Time of Update: 2023-02-01
Among the multinational original research enterprises, Pfizer, Sanofi, Merck, Lundbeck, AstraZeneca, Eisai and other enterprises are listed, of which Pfizer has the largest number of products, and 3 varieties are to be included, with cefoperazone sulbactam injection and voriconazole injection having a high market share.
-
On January 11, the traditional Chinese medicine sector fluctuated upward, and the industry generally showed a continuous positive trend
Time of Update: 2023-02-01
On January 11, the traditional Chinese medicine sector fluctuated to the upside, with Huasen Pharmaceutical rising by more than 5%, and Zhongsheng Pharmaceutical, Tongrentang, Taiji Group, Kangyuan Pharmaceutical, Yiling Pharmaceutical, etc.
-
【Cell Journal】Yang Shuo, Hu Zhibin and other joint studies of Southern Medical University have found a new mechanism for immune cells to regulate tumors
Time of Update: 2022-11-04
Recently, the research "Gasdermin D restricts anti-tumor immunity during PD-L1 checkpoint blockade" conducted by the team of professors Yang Shuo, Hu Zhibin and Yang Xi of Nanjing Medical University was published in the journal Cell Reports, reporting the effect of GSDMD-mediated pyrospiration of innate immune cells on tumor immunity and its mechanism of action.
-
HKU-Shenzhen Hospital completed the first clinical service case of brain "magnetic wave knife" in China
Time of Update: 2022-10-25
The University of Hong Kong-Shenzhen Hospital (hereinafter referred to as "HKU-Shenzhen Hospital") announced on the 18th that Mr. Wang, who has suffered from essential tremor for many years, recently successfully performed magnetic resonance guided focused ultrasound (MRgFUS, also known as "magnetic wave knife") treatment in the hospital, which solved the problem of tremor in the right hand.
-
Accuray Energy IoT platform helps the intelligent transformation of power grid infrastructure and the construction of smart microgrids
Time of Update: 2022-10-20
Ren Yunye Ankrui Electric Co. , Ltd. 201801 Abstract: After the "accelerating the construction of digital China" proposed in the 13th Five-Year Plan, the 14th Five-Year Plan proposed "the Internet-Int
-
JAMA: Longest OS Results for the Treatment of Extensive Small Cell Lung Cancer by Slulizumab (ASTRUM-005 Study
Time of Update: 2022-09-30
It is expected to benefit the world and fill the clinical gap Small cell lung cancer accounts for about 15% to 20% of bronchial lung cancer, and is the most aggressive subtype of lung cancer, divided into limited small cell lung cancer (LS-SCLC) and ES-SCLC.
-
【ITP changes because of you】Phase 2
Time of Update: 2022-06-10
"Clinical Practice Sharing Case 2 Basic Information: Gender: Female Age: 73-year-old initial platelet level: 1 × 109/L Hormone insufficiency: Hormone intolerance Table 2 Case 2 Follow-up and efficacy evaluation records Note: Eltrombopag is administered once a day (qd) .
-
The first domestic dictionary-type anti-Paris reading book "Anti-Paris Dictionary" was released 25 experts in the field of Parkinson's disease participated in the editing and review
Time of Update: 2022-04-23
Professor Chen Shengdi from the Department of Neurology, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, the leader of the society, pointed out that there are about 3 million Parkinson's disease patients in China, and the incidence rate of middle-aged and elderly people over 65 years old is 1.
-
Evaluation of the implementation of coronary stent centralized procurement: the comments of medical institutions have become an important indicator
Time of Update: 2022-01-25
The notice mentioned that the assessment objects are the city's medical insurance designated medical institutions (referred to as "medical institutions") that participate in the centralized procurement of coronary stents organized by the state, excluding those who did not participate in the report in the first year but purchased, and newly participated in the following year.
-
Urinary tract infections are prescribed "Levofloxacin + Clindamycin". Is it reasonable to use the combination or is it unnecessary
Time of Update: 2022-01-01
Especially in primary medical institutions, some patients with a history of high-risk diseases may choose to come to a community clinic for treatment because of a “minor disease” such as urinary tract infection.
-
Johnson & Johnson Ethicon resigns
Time of Update: 2022-01-01
On November 30, Johnson & Johnson Medical announced that Zhou Mintao, the general manager of Ethicon, would leave the company to seek outside career opportunities.
In February 2015, Zhou Mintao joined Johnson & Johnson Medical as the general manager of Ethicon China .
-
The Lancet: Infected people's "new crown" symptoms can last for one year
Time of Update: 2021-09-10
The largest longitudinal cohort study of hospitalized survivors of the new crown to date showed that the proportion of patients with at least one sequelae symptom dropped from 68% at 6 months to 49% at 12 months .
-
"Innovative Drug One Brother" Outbreak This month, 10 Class 1 New Drugs Intensively Strike
Time of Update: 2021-08-27
Sales of terminal anti-tumor drugs in physical pharmacies in cities in China (unit: ten thousand yuan) Source: Mi Nei. com, China's urban physical pharmacy terminal competition pattern For newly approved innovative drugs, retail pharmacies are the main battlefield for sales .
-
Notice on matters related to the registration of drug-device combination products (No. 52 of 2021
Time of Update: 2021-07-30
5. The applicant shall apply to the State Drug Administration for registration of drugs or medical devices according to the result of product attribute definition, and indicate "medicine and device combination products" in the application form .
-
China is approved for listing
Time of Update: 2021-04-23
▎The content team editor of WuXi AppTec recently announced on the official website of China National Medical Products Administration (NMPA) that Biogen's dimethyl fumarate (English trade name: Tecfidera; English common name: dimethyl fumarate) enteric-coated capsules The marketing application was officially approved for the treatment of relapsing multiple sclerosis (MS).
